UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines – The Manila…

SHENZHEN, China, Aug. 28, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") has officially announced the signing of a non-disclosure agreement (the "NDA") with Bowen Therapeutics Inc ("Bowen Therapeutics") for the acquisition of the Bowen Therapeutics laboratory at UMASS Medical School. This strategic move not only marks UTime's in-depth expansion in the global vaccine market, but also provides strong support for the registration of the relevant vaccine through the U.S. Food and Drug Administration (the "FDA").

One of the key drivers behind this acquisition is a growing global need for an effective monkeypox vaccine. Monkeypox, as an infectious disease caused by the monkeypox virus, has broken out in many places around the world in recent years, causing a high degree of alertness in the international community. Especially in the context of global epidemics, the speed and scope of its spread have led to significant public health challenges. According to the World Health Organization, cases of monkeypox have been reported in a number of countries and regions around the world, making the need for effective prevention and control measures and vaccines increasingly urgent.

View original post here:

UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines - The Manila...